이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Athenex 관리

관리 기준 확인 4/4

Athenex's CEO는 Johnson Lau, Jan2011 에 임명되었습니다 의 임기는 12.75 년입니다. 총 연간 보상은 $ 714.51K, 73.5% 로 구성됩니다. 73.5% 급여 및 26.5% 보너스(회사 주식 및 옵션 포함). 는 $ 3.93K 가치에 해당하는 회사 주식의 2.99% 직접 소유합니다. 3.93K. 경영진과 이사회의 평균 재임 기간은 각각 4.5 년과 4.9 년입니다.

주요 정보

Johnson Lau

최고 경영자

US$714.5k

총 보상

CEO 급여 비율	73.5%
CEO 임기	12.8yrs
CEO 소유권	3.0%
경영진 평균 재임 기간	4.5yrs
이사회 평균 재임 기간	4.9yrs

최근 관리 업데이트

Recent updates

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts

Mar 06

Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?

Feb 19

When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

Jan 29

CEO 보상 분석

Johnson Lau 의 보수는 Athenex 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2022	US$715k	US$525k	-US$98m
Sep 30 2022	n/a	n/a	-US$178m
Jun 30 2022	n/a	n/a	-US$192m
Mar 31 2022	n/a	n/a	-US$198m
Dec 31 2021	US$2m	US$525k	-US$158m
Sep 30 2021	n/a	n/a	-US$132m
Jun 30 2021	n/a	n/a	-US$135m
Mar 31 2021	n/a	n/a	-US$144m
Dec 31 2020	US$3m	US$161k	-US$142m
Sep 30 2020	n/a	n/a	-US$118m
Jun 30 2020	n/a	n/a	-US$116m
Mar 31 2020	n/a	n/a	-US$108m
Dec 31 2019	US$4m	US$519k	-US$123m
Sep 30 2019	n/a	n/a	-US$129m
Jun 30 2019	n/a	n/a	-US$141m
Mar 31 2019	n/a	n/a	-US$145m
Dec 31 2018	US$3m	US$500k	-US$117m
Sep 30 2018	n/a	n/a	-US$119m
Jun 30 2018	n/a	n/a	-US$96m
Mar 31 2018	n/a	n/a	-US$97m
Dec 31 2017	US$5m	US$500k	-US$131m
Sep 30 2017	n/a	n/a	-US$143m
Jun 30 2017	n/a	n/a	-US$144m
Mar 31 2017	n/a	n/a	-US$118m
Dec 31 2016	US$522k	US$200k	-US$88m

보상 대 시장: Johnson 의 총 보상 ($USD 714.51K )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 683.56K ).

보상과 수익: Johnson 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Johnson Lau (63 yo)

12.8yrs

테뉴어

US$714,505

보상

Dr. Yiu-Nam Lau, also known as Johnson, MBBS, MD, FRCP, Ph D., has been the Chief Executive Officer of Athenex, Inc. since 2011. Dr. Lau is the Vice Chairman and CEO of Axis Therapeutics.Dr. Lau serves as...

리더십 팀

이름	위치	테뉴어	보상	소유권
Yiu-Nam Lau	Chairman & CEO	12.8yrs	US$714.51k	2.99% $ 3.9k
Jeffrey Yordon	COO & President of Athenex Pharmaceutical Division	6.7yrs	US$524.66k	0.14% $ 186.9
Daniel Lang	President of Athenex Cell Therapy	2.4yrs	US$481.15k	0.047% $ 62.0
Allen Barnett	Co-Founder & President Emeritus	12.8yrs	데이터 없음	데이터 없음
Steven Adams	Chief Accounting Officer	2.2yrs	US$289.28k	0.0018% $ 2.4
Caileigh Dougherty	Director of Investor Relations	no data	데이터 없음	데이터 없음
Jacqueline Li	Vice President of Alliance Management & Corporate Development	3.8yrs	데이터 없음	데이터 없음
John Matthei	Chief Human Resource Officer	no data	데이터 없음	데이터 없음
David Cutler	Deputy Chief Medical Officer of Biologics & Cell Therapy	3.8yrs	데이터 없음	데이터 없음
Timothy Cook	Chief Business & Commercial Officer of Proprietary Drugs	5.3yrs	데이터 없음	0.048% $ 62.9
Nicholas Campbell	Chief Restructuring Officer	less than a year	데이터 없음	데이터 없음
Li Shen	Vice President of Financial Planning & Treasury	6.8yrs	데이터 없음	데이터 없음

4.5yrs

평균 재임 기간

59yo

평균 연령

경험이 풍부한 관리: ATNX.Q 의 관리팀은 경험 ( 4.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Yiu-Nam Lau	Chairman & CEO	19.9yrs	US$714.51k	2.99% $ 3.9k
John Vierling	Independent Director	4.5yrs	US$42.00k	0.14% $ 187.4
Jinn Wu	Independent Director	16.5yrs	US$40.86k	0.40% $ 529.0
Robert Jay Spiegel	Independent Director	3.2yrs	US$46.00k	0.053% $ 69.8
Kwan-Hung Tsang	Independent Director	5.3yrs	US$55.14k	0.20% $ 257.2
Jordan Kanfer	Independent Director	4.5yrs	US$42.00k	0.0099% $ 13.0
Manson Fok	Director	8.3yrs	US$35.71k	1.28% $ 1.7k
Stephanie Davis	Lead Independent Director	4.5yrs	US$46.00k	0.093% $ 121.8

4.9yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 이사회: ATNX.Q 의 이사회는 경험(평균 재직 기간 4.9 년)으로 간주됩니다.

Athenex 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Insufficient new directors

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Insufficient new directors

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Recent updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Motion for Asset Sale Filed by Athenex, Inc.

Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)

Athenex Announces Reverse Stock Split

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Price target decreased to US$2.17

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.

Athenex prices $30M in stock and warrants offering

Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex

Athenex surges 70% as Dr Reddy's and Intas race to form buyout deal

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex GAAP EPS, revenue misses estimates

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million.

Athenex to sell its China API business for $19M

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target decreased to US$4.50

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Price target decreased to US$4.50

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$5.50

Price target increased to US$6.67

Athenex Announces Appoints Joe Annoni as Chief Financial Officer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021

Independent Director recently bought US$61k worth of stock

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)

Independent Director recently bought US$161k worth of stock

Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.

Chief Financial Officer Randoll Sze has left the company

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)

Consensus EPS estimates fall to -US$1.31

Price target decreased to US$7.50

Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)

Independent Director exercised options to buy US$230k worth of stock.

Consensus EPS estimates increase to -US$1.42

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021

Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited.

Athenex EPS beats by $0.13, beats on revenue

Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Athenex, Inc

Is Athenex (NASDAQ:ATNX) Weighed On By Its Debt Load?

Robbins LLP Reminds Shareholders that Athenex, Inc. is Being Sued for Misleading Shareholders

Chairman & CEO exercised options to buy US$98k worth of stock.

Insider recently sold US$1.9m worth of stock

Have Insiders Sold Athenex, Inc. (NASDAQ:ATNX) Shares Recently?

Analysts lower revenue estimates to US$115.2m

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts